Table 1 Patient characteristics
Characteristics | All | Single metastasis | Multiple metastases | ||
|---|---|---|---|---|---|
Number | 271 | 169 (62%) | 102 (38%) | ||
Stage at diagnosis | |||||
 I | 37 (14%) | 24 (14%) | 13 (13%) | ||
 IIA + IIB | 84 + 89 (64%) | 58 + 53 (66%) | 62 (61%) | ||
 IIIA+IIIB+IIIC | 32 + 22 + 7 (22%) | 18 + 12 + 4 (20%) | 27 (26%) | ||
Adjuvant chemotherapy | |||||
 Yes | 184 (68%) | 115 (68%) | 69 (68%) | ||
 No | 87 (32%) | 54 (32%) | 33 (32%) | ||
Median age at recurrence (range, years) | 62 (29–92) | 62 (29–90) | 63 (33–92) | ||
Median OS after recurrence (range, years) | 4.58 (0.02–13.53) | 5.86 (0.04–13.53) | 2.50 (0.02–12.21) | ||
DFI (median, years) | 4.01 (0.35–16.85) | 3.98 (0.58–12.02) | 4.04 (0.35–16.85) | ||
< 2 years | 56 (21%) | 35 (21%) | 21 (21%) | ||
≥2 years | 215 (79%) | 134 (79%) | 81 (79%) | ||
CEA/CA15–3 serum level | |||||
 Normal | 106 (47%) | 81 (57%) | 25 (30%) | ||
 High | 120 (53%) | 62 (43%) | 58 (70%) | ||
Initial therapy for reccurence | |||||
 Endocrine therapy | 173 (64%) | 119 (70%) | 54 (53%) | ||
 Chemotherapy | 83 (31%) | 42 (25%) | 41 (40%) | ||
 unknown | 15 (5%) | 8 (5%) | 7 (7%) | ||
Metastatic organ site | Â | All | Diffuse lesions | Non-diffuse lesions | Â |
All | 271 | 169 | 90 (53%) | 79 (47%) | 102 |
Bone | 148 (55%) | 85 (50%) | 46 (54%) | 39 (46%) | 63 (62%) |
Lymph node | 95 (35%) | 31 (18%) | 13 (42%) | 18 (58%) | 64 (63%) |
Lung | 74 (27%) | 24 (14%) | 17 (71%) | 7 (29%) | 50 (49%) |
Liver | 54 (20%) | 14 (8%) | 7 (50%) | 7 (50%) | 40 (39%) |
Pleural | 41 (15%) | 12 (7%) | 6 (50%) | 6 (50%) | 29 (28%) |
Brain | 8 (3%) | 1 (1%) | 1 (100%) | 0 (0%) | 7 (7%) |
Others | 2 (1%) | 2 (1%) | 0 (0%) | 2 (100%) | 0 (0%) |